

## AGM Dates & Nominations

In accordance with ASX Listing Rule 3.13.1, **Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company")** advises that it anticipates that it will hold its next Annual General Meeting ('AGM') on 18 November 2021.

The closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 7 October 2021. Any nominations must be received in writing no later than 5.00pm (WST) on 7 October 2021 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM including the time of the AGM in a separate Notice of Meeting, which will be provided to shareholders in October 2021. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website at [www.neurotechinternational.com](http://www.neurotechinternational.com).

---

### Authority

This announcement has been authorised for release by Winton Willesee, Director.

### Further Information

Winton Willesee  
Non-Executive Director  
[winton@azc.com.au](mailto:winton@azc.com.au)  
+61 (0)41 066 7844

### Media:

Juliana Roadley  
IR Department  
[juliana.roadley@irdepartment.com.au](mailto:juliana.roadley@irdepartment.com.au)  
+61 (0)41 488 9863

### About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>